1. |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
|
2. |
Hölzel D, Eckel R, Bauerfeind I, et al. Survival of de novo stage IV breast cancer patients over three decades. J Cancer Res Clin Oncol, 2017, 143(3): 509-519.
|
3. |
Xiong Z, Deng G, Huang X, et al. Score for the survival probability in metastasis breast cancer: a nomogram-based risk assessment model. Cancer Res Treat, 2018, 50(4): 1260-1269.
|
4. |
Mariotto AB, Etzioni R, Hurlbert M, et al. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev, 2017, 26(6): 809-815.
|
5. |
中国女医师协会乳腺疾病研究中心. 中国进展期乳腺癌共识指南 2020(CABC3). 癌症进展, 2020, 18(19): 1945-1964.
|
6. |
Khan S, Zhao F, Solin L, et al. A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: a trial of the ECOG-ACRIN Research Group (E2108). J Clin Oncol, 2020, 38(18 Suppl): LBA2-LBA2.
|
7. |
Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol, 2015, 16(13): 1380-1388.
|
8. |
Fitzal F, Bjelic-Radisic V, Knauer M, et al. Impact of breast surgery in primary metastasized breast cancer: outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE Trial. Ann Surg, 2019, 269(6): 1163-1169.
|
9. |
Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol, 2020, 31(12): 1623-1649.
|
10. |
Liu D, Wu J, Lin C, et al. Breast subtypes and prognosis of breast cancer patients with initial bone metastasis: a population-based study. Front Oncol, 2020, 10: 580112.
|
11. |
杨宏伟, 陈茂山, 李芳芳, 等. 年龄与三阴性乳腺癌临床病理特征及预后的关系. 中国普通外科杂志, 2021, 30(11): 1285-1293.
|
12. |
Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR Statement. JAMA, 2021, 326(16): 1614-1621.
|
13. |
唐林, 陈巍魏, 管晓翔. AJCC 第 8 版乳腺癌分期系统更新的解读. 临床肿瘤学杂志, 2017, 22(11): 1038-1040.
|
14. |
郭世坤, 胡潺潺, 徐壮语, 等. 初治Ⅳ期乳腺癌患者外科治疗对生存影响的 meta 分析. 中国普外基础与临床杂志, 2020, 27(5): 588-594.
|
15. |
陈琳, 乐一帆, 齐晓伟. 新发Ⅳ期乳腺癌患者接受手术治疗可提高总生存率. 中华乳腺病杂志(电子版), 2018, 12(2): 119.
|
16. |
Soran A, Ozmen V, Ozbas S, et al. Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: Protocol MF07-01. Ann Surg Oncol, 2018, 25(11): 3141-3149.
|
17. |
王倩, 孙冰, 孟祥颖, 等. 乳腺癌单纯骨转移患者预后相关因素分析. 中华肿瘤防治杂志, 2018, 25(5): 353-358.
|
18. |
Botteri E, Munzone E, Intra M, et al. Role of breast surgery in T1-3 breast cancer patients with synchronous bone metastases. Breast Cancer Res Treat, 2013, 138(1): 303-310.
|
19. |
Mulcrone PL, Campbell JP, Clément-Demange L, et al. Skeletal colonization by breast cancer cells is stimulated by an osteoblast and β2ar-dependent neo-angiogenic switch. J Bone Miner Res, 2017, 32(7): 1442-1454.
|
20. |
Sathiakumar N, Delzell E, Morrisey MA, et al. Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U. S. Medicare beneficiaries, 1999-2006. Breast Cancer Res Treat, 2012, 131(1): 231-238.
|
21. |
Xiong Z, Deng G, Wang J, et al. Could local surgery improve survival in de novo stage IV breast cancer?. BMC Cancer, 2018, 18(1): 885.
|
22. |
陈茂山, 李芳芳, 杨宏伟, 等. 基于 SEER 数据库分析 142007 例乳腺癌诊断时婚姻状态与预后的关系. 重庆医科大学学报, 2020, 45(11): 1567-1572.
|
23. |
Chen MT, Sun HF, Zhao Y, et al. Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis. Sci Rep, 2017, 7(1): 9254.
|
24. |
Ren JX, Gong Y, Ling H, et al. Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics. Breast Cancer Res Treat, 2019, 173(1): 225-237.
|
25. |
Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol, 2010, 28(1): 92-98.
|
26. |
Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol, 2017, 18(6): 732-742.
|
27. |
Arpino G, Wiechmann L, Osborne CK, et al. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev, 2008, 29(2): 217-233.
|
28. |
Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst, 2004, 96(12): 926-935.
|
29. |
Ma L, Mi Y, Cui S, et al. Role of locoregional surgery in patients with de novo stage IV breast cancer: analysis of real-world data from China. Sci Rep, 2020, 10(1): 18132.
|